Resmed (RSMDF) Raw Materials (2010 - 2026)

Resmed (RSMDF) has reported Raw Materials for 17 consecutive years, with $396.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Raw Materials rose 7.85% year-over-year to $396.1 million; the trailing twelve-month figure through Jun 2026 stood at $396.1 million (up 7.85% YoY), and the FY2026 full-year result was $396.1 million, up 7.85% from the prior year.
• Raw Materials improved to $396.1 million in Q2 2026 per RSMDF's latest filing, from $350.9 million in the prior quarter.
• Across five years, Raw Materials topped out at $468.8 million in Q1 2023 and bottomed at $340.3 million in Q1 2022.
• Historically, Raw Materials has averaged $393.1 million across 5 years, with a median of $374.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Raw Materials jumped 134.0% in 2022, then decreased 22.56% in 2024.
• Over 5 years, Raw Materials stood at $463.4 million in 2022, then climbed by 0.82% to $467.2 million in 2023, then slipped by 21.92% to $364.8 million in 2024, then climbed by 2.72% to $374.7 million in 2025, then gained by 5.71% to $396.1 million in 2026.
• According to Business Quant data, Raw Materials over the past three periods registered $396.1 million, $350.9 million, and $374.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.